Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 5/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.45 |
| ▸ | CACNB1 | Q02641 | 5/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20187534 | 0.88 | CACNA2D1 (0.49) | CACNA2D1CACNA1BCACNB1CACNA1CALDH1A1 | |
| SCHEMBL30741639 | 0.83 | CACNA2D1 (0.39) | CACNA2D1CACNA1BCACNB1CACNA1CALDH1A1 | |
| SCHEMBL20199981 | 0.81 | DRD4 (0.43) | CACNA2D1CACNA1BCACNB1CACNA1CALDH1A1 | |
| SCHEMBL1387733 | 0.81 | ALDH1A1 (0.43) | CACNA2D1CACNA1BCACNB1CACNA1CALDH1A1 | |
| SCHEMBL22403100 | 0.80 | CACNA2D1 (0.45) | CACNA2D1CACNA1BCACNB1CACNA1CALDH1A1 | |
| SCHEMBL9080067 | 0.78 | ALDH1A1 (0.42) | CACNA2D1CACNA1BCACNB1CACNA1CALDH1A1 | |
| SCHEMBL20191192 | 0.78 | ALDH1A1 (0.45) | CACNA2D1CACNA1BCACNB1CACNA1CALDH1A1 | |
| SCHEMBL20187616 | 0.78 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL1387794 | 0.76 | MEN1 (0.42) | CACNA2D1CACNA1BCACNB1CACNA1CALDH1A1 | |
| SCHEMBL20187501 | 0.73 | ALDH1A1 (0.38) | CACNA2D1CACNA1BCACNB1CACNA1CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814369-B2 | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-11-14 | — | — | US | claimed |
| US-20210221798-A1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-07-22 | — | — | US | claimed |
| US-11814369-B2 | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-11-14 | — | — | US | disclosed |
| US-20210221798-A1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-07-22 | — | — | US | disclosed |
| US-10975060-B2 | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-04-13 | — | — | US | disclosed |
| US-20200283420-A1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-09-10 | — | — | US | disclosed |
| EP-3544964-B1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | Bayer Pharma AG (DE) | 2020-06-17 | — | — | EP | disclosed |
| EP-3544964-A1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | Bayer Pharma Aktiengesellschaft (DE) | 2019-10-02 | — | — | EP | disclosed |
| WO-2018096082-A1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283420-A1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | RXFP1, RXFP2, RXFP3 | CACNA2D1 1974/4885CACNA1B 101/4885CACNB1 279/4885 |
| US-11814369-B2 | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging | RXFP1, RXFP2, RXFP3 | CACNA2D1 1974/4885CACNA1B 101/4885CACNB1 279/4885 |
| US-10975060-B2 | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging | RXFP1, RXFP2, RXFP3 | CACNA2D1 1974/4885CACNA1B 101/4885CACNB1 279/4885 |
| US-20210221798-A1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | RXFP1, RXFP2, RXFP3 | CACNA2D1 1974/4885CACNA1B 101/4885CACNB1 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.